GVP Module VI sets the EU rules for individual cases (from Article 107 of Directive 2001/83/EC):
- Serious valid ICSRs, from inside or outside the EU (including those received from authorities outside the EU), go to EudraVigilance only, within 15 days.
- Non-serious valid ICSRs that occur in the EU go to EudraVigilance within 90 days. Non-serious cases from outside the EU are not submitted.
- These rules apply whatever the condition of use and whether or not the reaction is expected.
- EudraVigilance forwards each ICSR to the competent authority of the member state where the reaction occurred.
Literature. The European Medicines Agency monitors selected medical literature for a published list of active substances (Article 27 of Regulation 726/2004) and enters those cases in EudraVigilance. For those substances and that literature, companies do not submit the ICSRs themselves; they can access and download them.
Signals. Companies monitor EudraVigilance data for their substances. An emerging safety issue is notified no later than 3 working days after it is established (GVP Module IX).